Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) Market Size, Clinical Trials, Product Pipelines and Investment Trends, till 2032

Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) Market Size is estimated to be $2485 million in 2024 and is expected to grow at an average yearly rate of around 5% during the timeframe (2025-2032).

What is Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) and what are the growth drivers of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) Market?

Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) are a class of drugs used primarily for the treatment of heart failure, particularly heart failure with reduced ejection fraction (HFrEF). ARNIs combine two pharmacological mechanisms: the inhibition of neprilysin, an enzyme responsible for the degradation of natriuretic peptides, and the blockade of angiotensin II type-1 (AT1) receptors. By inhibiting neprilysin, ARNIs increase the levels of beneficial natriuretic peptides that promote vasodilation, natriuresis, and diuresis. Simultaneously, angiotensin receptor blockade reduces the harmful effects of the renin-angiotensin-aldosterone system (RAAS), such as vasoconstriction, sodium retention, and adverse cardiac remodeling. The most prominent ARNI on the market is sacubitril/valsartan, a fixed-dose combination that has demonstrated superior efficacy compared to traditional angiotensin-converting enzyme (ACE) inhibitors in clinical trials.

Rising Prevalence of Heart Failure

One of the primary growth drivers of the ARNI market is the increasing global burden of heart failure. With aging populations and a rising prevalence of associated risk factors such as hypertension, diabetes, and coronary artery disease, the number of heart failure cases continues to grow. This creates a strong demand for effective and advanced therapeutic options like ARNIs, which have proven clinical benefits in reducing mortality and hospitalization rates among heart failure patients.

Advancements in Clinical Guidelines

Another key driver of ARNI market growth is the inclusion of ARNIs in major clinical guidelines for heart failure treatment. Leading health organizations now recommend ARNIs as a first-line therapy for certain patients with HFrEF. This endorsement has significantly improved the awareness and acceptance of ARNIs among healthcare professionals and has increased their adoption in clinical practice, contributing to market expansion.

Improved Patient Outcomes and Quality of Life

The ability of ARNIs to improve patient outcomes is a strong incentive for their continued use and development. Compared to standard therapies, ARNIs have shown better results in terms of reducing cardiovascular mortality and heart failure-related hospitalizations. These outcomes not only extend patients' lives but also improve their quality of life, making ARNIs a preferred choice for long-term management of chronic heart failure.

Growing Healthcare Expenditure and Access

Rising healthcare spending, especially in emerging economies, is enabling greater access to advanced therapies like ARNIs. As healthcare infrastructure improves and insurance coverage expands, more patients can afford high-cost medications, which supports market growth. Furthermore, increased investment in research and development by pharmaceutical companies is expected to lead to the introduction of new ARNI formulations and indications.

Awareness Campaigns and Early Diagnosis

Efforts to improve awareness about heart failure and its management also play a crucial role in driving the ARNI market. Public health campaigns and advancements in diagnostic technologies are facilitating earlier diagnosis and treatment initiation, thereby increasing the potential patient population for ARNIs.



The research and analytics firm Datavagyanik released the updated version of its report on "Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) Market - Detailed Analysis, Business Opportunities and Forecasts".

Request sample at https://datavagyanik.com/reports/angiotensin-receptor-neprilysin-inhibitors-arnis-market/

Clinical Trials in Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) Market and New Product Pipelines

The pipeline for angiotensin receptor-neprilysin inhibitors (ARNIs) continues to expand as researchers explore their efficacy, safety, and therapeutic range. Initial landmark clinical trials, such as those investigating sacubitril/valsartan, laid the groundwork for demonstrating benefits in heart failure with reduced ejection fraction (HFrEF) and hinted at potential in heart failure with preserved ejection fraction (HFpEF). Building on this success, newer trials are extending into broader cardiovascular, renal, and metabolic contexts to redefine standard care.

Ongoing Heart Failure Trials

Several pivotal trials are currently assessing ARNIs in heart failure subgroups. One major study is evaluating sacubitril/valsartan in acute decompensated heart failure, aiming to confirm early initiation post-admission can reduce readmissions and all-cause mortality. Parallel trials examine the effects of ARNI therapy in patients with HFpEF, where elevated filling pressures but preserved ejection fraction challenge treatment strategies. These studies are investigating whether combining neprilysin inhibition with angiotensin receptor blockade can favorably influence outcomes such as exercise tolerance, hospitalization rates, and long-term mortality.

Renal Protection Studies

ARNIs are being investigated beyond the heart in chronic kidney disease (CKD) and diabetic nephropathy. New trials assess whether sacubitril/valsartan slows progression of proteinuria and protects renal function compared to angiotensin receptor blockers alone. Researchers are exploring whether enhanced natriuretic peptide activity can reduce intraglomerular hypertension and fibrosis. Results from phase II and III programs may support label expansion into nephrology, opening new therapeutic avenues and broadening the potential patient base.

Metabolic and Hypertension Research

Interest in ARNIs is growing within metabolic and hypertension fields. Trials now explore dual-action effects in obesity-related hypertension and metabolic syndrome, testing whether ARNIs can offer superior blood pressure control alongside favorable impacts on insulin sensitivity and lipid profile. Investigators aim to determine if these agents can serve as multifaceted therapies addressing both cardiovascular and metabolic derangements.

Novel ARNI Formulations and Combinations

Development in the ARNI space includes next-generation molecules and innovative delivery systems. Several candidates are under evaluation, such as ARNI compounds with enhanced neprilysin selectivity or alternative angiotensin receptor moieties. Additionally, fixed-dose combinations with mineralocorticoid receptor antagonists or SGLT2 inhibitors are under early-stage assessment. These combinations aim to maximize benefit across the cardio-renal-metabolic continuum, offering simplified regimens and improved adherence.

Safety and Tolerability Trials

Given the dual mechanisms of ARNIs, trial protocols consistently emphasize long-term safety. Current studies are monitoring potential hypotension, renal impairment, electrolyte disturbances, and angioedema across diverse patient populations, including older adults and those with multi-morbidity. Post-marketing surveillance programs and real-world evidence registries aim to refine dosing algorithms, assess rare adverse events, and guide patient selection in clinical practice.

Pediatric and Special Populations

New horizons include pediatric heart failure, congenital heart disease, and chemotherapy-induced cardiomyopathy. While most ARNI trials have focused on adults, emerging programs are evaluating age-appropriate dosing, safety profiles, and efficacy in younger cohorts. Additionally, trials are examining whether ARNIs can mitigate cardiac remodeling in cancer survivors or post-transplant patients, potentially expanding indications and addressing unmet needs.

Request for customization https://datavagyanik.com/reports/angiotensin-receptor-neprilysin-inhibitors-arnis-market/



Important target segments driving the demand for Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) Market

The global demand for Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) is being driven by several key patient and healthcare segments. These target populations are characterized by high cardiovascular disease burden, chronic conditions, and evolving treatment needs. As awareness grows and clinical evidence expands, the adoption of ARNIs is increasing among both traditionally recognized and emerging therapeutic groups.

Heart Failure with Reduced Ejection Fraction (HFrEF) Patients

The largest and most significant target segment in the ARNI market consists of patients with heart failure with reduced ejection fraction. These individuals represent the primary indication for ARNI therapy, based on robust clinical data showing improved survival and reduced hospitalizations compared to standard ACE inhibitor therapy. This segment includes a growing number of elderly patients, especially in developed nations, where heart failure incidence continues to rise due to aging populations and improved acute care that prolongs life after cardiac events.

Heart Failure with Preserved Ejection Fraction (HFpEF) Patients

Another important emerging segment includes patients with heart failure with preserved ejection fraction. Although treatment options for HFpEF have historically been limited, recent trials have shown promising results for ARNIs in this group. This population is often characterized by older age, female gender, and multiple comorbidities such as hypertension, diabetes, and obesity. As more evidence supports ARNI use in HFpEF, demand from this growing demographic is expected to rise.

High-Risk Cardiovascular Patients

Patients at high risk for cardiovascular events-such as those with a history of myocardial infarction, hypertension, or structural heart disease-represent another potential growth area for ARNIs. These patients may benefit from early introduction of ARNI therapy to prevent progression to symptomatic heart failure. In many cases, preventive cardiology clinics and risk-based management models are identifying these individuals earlier, driving interest in therapies with proven long-term outcome benefits.

Chronic Kidney Disease (CKD) Patients

Individuals with chronic kidney disease, especially those with concurrent heart failure or hypertension, are becoming a focal point for ARNI therapy. These patients often exhibit overlapping cardio-renal syndromes, and ARNIs have shown promise in reducing renal decline while providing cardiovascular protection. As more clinical trials explore these effects, CKD patients are likely to become a substantial contributor to market growth.

Geriatric Population

The aging population globally is another critical target segment. Elderly patients are disproportionately affected by heart failure and other chronic cardiovascular conditions. As ARNI formulations and dosing guidelines adapt to the needs of older adults, including those with frailty and polypharmacy considerations, this demographic is poised to drive significant demand for well-tolerated, effective therapies like ARNIs.

Diabetic and Metabolic Syndrome Patients

Patients with diabetes or metabolic syndrome are also an increasingly relevant target group. These individuals face elevated cardiovascular risk and often develop heart failure as a complication. ARNIs offer a dual mechanism of action that may provide benefits beyond traditional therapies. As more studies explore ARNI use in this population, their adoption in endocrinology and internal medicine practices is likely to grow.


Key Players in Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Market Share

The global market for Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) is currently led by a small number of pharmaceutical companies that developed and commercialized the first-in-class therapy. These players have established a strong presence through R&D investments, strategic licensing, marketing efforts, and partnerships. Market dynamics are shaped by their efforts to maintain and expand share while competition emerges with novel formulations and pipeline compounds.

Dominant Market Leader: Novartis

Novartis holds the dominant position in the ARNI market thanks to its flagship product, sacubitril/valsartan (branded as Entresto). As the first ARNI approved globally, Entresto commands a substantial share of ARNI prescriptions and revenues. Its strong clinical profile, broad labeling across heart failure subtypes, and aggressive market penetration in key geographies like North America, Europe, and Asia underpin Novartis's leadership. The company enjoys a high single-digit compound annual growth rate tied to label expansions into areas like heart failure with preserved ejection fraction and post-myocardial infarction. Entresto's strong presence in emerging economies, driven by licensing deals and government partnerships, contributes to Novartis's robust market hold.

Emerging Competitors and Biosimilars

Although no direct generic equivalent to sacubitril/valsartan exists currently, several pharmaceutical firms are preparing biosimilar or generic ARNI candidates. Indian generic drug manufacturers and companies in China and Eastern Europe are investing in bioequivalent therapies aimed at reducing costs in their markets. These potential entrants could erode the market share of Entresto once patent protections expire. Their impact will depend on regulatory clearance, price competitiveness, and physician acceptance. Until generics become available, Novartis remains unchallenged by branded ARNI alternatives.

Pipeline Contenders from Mid‐Size Pharma

Several mid‐size pharmaceutical companies and biotech firms are developing next‐generation ARNIs or combination therapies that could compete with sacubitril/valsartan. These include ARNI molecules paired with mineralocorticoid receptor antagonists, SGLT‐2 inhibitors, or other cardiovascular agents. While none have reached late‐stage trials yet, some early‐stage data indicate potential in heart failure subtypes and chronic kidney disease. These pipeline contenders currently hold negligible market share but may gradually capture niche segments, especially in regions with progressive regulatory pathways.

Collaborative Developments and Licensing Agreements

Strategic partnerships are shaping future ARNI competition. Novartis has entered collaborations with academic institutions and biotech firms to co-develop novel ARNI-based combinations. Other companies are forming licensing agreements to secure rights for ARNI candidates in specific regions or indications. Licensing deals in Latin America, Southeast Asia, and parts of Africa aim to strengthen pipeline diversity and expand geographic reach. Such collaborations allow companies to share development costs, accelerate regulatory filings, and enter underserved markets more effectively.

Geographic Market Disparities

ARNI adoption and market share vary significantly by region. North America remains the largest market, with Entresto accounting for more than half of ARNI prescriptions. Europe also shows strong uptake, supported by guideline endorsements, though uptake in Eastern Europe and Russia is slower. In Asia-Pacific, Japan, Australia, and South Korea exhibit moderate penetration, while Brazil and China are emerging markets for ARNIs. Novartis's regional subsidiaries and local distributors manage point-of-care adoption and pricing strategies catered to each geography.

Future Prospects and Competitive Threats

Looking forward, several dynamics could reshape the future ARNI landscape. The eventual entry of generics or biosimilars will cut into market share and pressure pricing. Second-generation ARNI formulations and combination products may capture patients who underperform on sacubitril/valsartan or have multiple comorbidities. Additionally, strategic collaborations and licensing deals may elevate mid-size players into competitive positions. Nevertheless, until generics and generational competitors materialize, Novartis remains the undisputed industry leader in the ARNI market.


Key Questions Answered in the Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) market report:

What is the total global Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) Sales, and how has it changed over the past five years?

What is Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) investment trend?

Which countries have the highest Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), and what factors contribute to their dominance in the market?

How does Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) Sales vary across key manufacturers, and what expansions have been observed recently?

What is the current global revenue generated from Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) Sales, and how does it compare to previous years?

Which industries drive the highest demand for Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), and how is this demand expected to evolve in the next five years?

What are the major challenges impacting Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) industry and supply chain operations across key markets?

How do government policies, environmental regulations, and trade restrictions affect Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) and market dynamics?

Related Studies:

Interleukin-6 (IL-6) Inhibitors Market
https://datavagyanik.com/reports/interleukin-6-il-6-inhibitors-market/ re/

Interleukin-4 & 13 (IL-4/IL-13) Inhibitors Market
https://datavagyanik.com/reports/interleukin-4-13-il-4-il-13-inhibitors-market/

Galectin-3 Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market
https://datavagyanik.com/reports/galectin-3-inhibitors-for-idiopathic-pulmonary-fibrosis-ipf-market/

PDE4 (Phosphodiesterase-4) Inhibitors for Idiopathic Pulmonary Fibrosis (IPF) Market
https://datavagyanik.com/reports/pde4-phosphodiesterase-4-inhibitors-for-idiopathic-pulmonary-fibrosis-ipf-market/

Enzyme Replacement Therapy for Hunter Syndrome Market
https://datavagyanik.com/reports/enzyme-replacement-therapy-for-hunter-syndrome-market/

IT Park, Dehradun, UK

Datavagyanik is a business intelligence firm with clients worldwide. We provide the right knowledge and advisory to business organizations and help them to grow and excel. We specialize in areas such as Pharmaceutical, Healthcare, Manufacturing, Consumer Goods, Materials & Chemicals and others. We specialize in market sizing, forecasting, supply chain analysis, supplier intelligence, import-export insights, market trend analysis and competitive intelligence.

Contact us:

Peter (Sales Head)
Phone: +1-330-440-0311
Website: https://datavagyanik.com/
Linkedin: https://www.linkedin.com/company/datavagyanik-business-intelligence-solutions/
Email: sales@datavagyanik.com

This release was published on openPR.